{
}
The Swiss stock market continued its upward trend, with the SMI rising 0.5% to 12,420 points, fueled by optimism over potential trade deals and peace talks regarding Ukraine. Sika led the blue-chip gains with a 1.9% increase, while UBS faced pressure amid concerns over stricter capital requirements. VAT Group's shares fell 2.6% as it revised its sales growth outlook for 2025-2029.
UBS warns that rising protectionism may lead Swiss companies to relocate production abroad, potentially undermining the country's long-term growth. A survey reveals that half of larger firms considering new outlets are focused on the U.S., with significant investments announced by Novartis and Roche. Economists predict a slowdown in Swiss growth, forecasting a 1% GDP increase for 2025, down from 1.5%.
Swiss companies are increasingly considering relocation due to rising protectionism and tariffs, with half of exporters exploring new markets. A significant 50% of firms focused on the U.S. view relocation as likely, while only 25% of SMEs are contemplating such moves. UBS warns that these trends could hinder Switzerland's long-term economic growth, which is already projected to slow to 1% in 2025.
Swiss CEOs and board members, including UBS's Sergio Ermotti and Holcim's Jan Jenisch, often receive significantly higher compensation than reported due to undervalued share portfolios. For instance, Ermotti's 2023 earnings could have reached CHF 18.4 million if shares were valued accurately, while Jenisch's total compensation included CHF 48 million, largely from stock options. Roche's Severin Schwan and Nestlé's Mark Schneider also illustrate this trend, with substantial portions of their pay linked to undervalued shares.
Swiss CEOs, including UBS's Sergio Ermotti and Holcim's Jan Jenisch, are criticized for receiving substantial hidden bonuses due to undervalued share packages. Ethos Foundation highlights that these packages are often valued significantly below market rates, inflating actual remuneration over time. For instance, Ermotti's compensation could have reached CHF 18.4 million if shares were valued correctly, while Roche's Severin Schwan also benefits from similar undervaluation practices.
UBS has rated Roche Holdings AG as 'Buy', indicating a positive outlook on the stock. However, the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investors are cautioned about the risks involved in purchasing securities, which may lead to total capital loss.
Roche Holding AG operates in healthcare research, divided into Pharmaceuticals and Diagnostics. The Pharmaceuticals Division includes Roche Pharmaceuticals and Chugai, focusing on drug development for oncology, immunology, and more, with notable products like Avastin and MabThera. The Diagnostics Division offers advanced tools for cell analysis and gene expression.
UBS has rated Roche Holdings AG as a 'Buy'. The information provided is for informational purposes only and does not constitute a recommendation to buy or sell securities. Investing in securities carries risks, including the potential loss of the entire capital invested.
Roche Holding AG operates in healthcare research, divided into Pharmaceuticals and Diagnostics. The Pharmaceuticals Division includes Roche Pharmaceuticals and Chugai, focusing on drug development for oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Its Diagnostics Division encompasses Diabetes Care, Molecular Diagnostics, Professional Diagnostics, and Tissue Diagnostics, offering products for researchers in cell analysis and genome sequencing.
The Swiss stock market closed slightly higher, with the SMI rising 0.15% to 12,893.98 points, buoyed by gains in cyclical and financial stocks. Notable performers included OC Oerlikon (+8.7%) and Basilea (+8.3%), while Lonza (-2.7%) and Siegfried (-6.3%) faced declines due to conservative outlooks. Encouraging economic signals from Germany and the USA contributed to a positive market sentiment.
Roche Holding AG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Swiss stock market rises as UBS faces pressure from potential capital requirements
Novartis AG
Sika AG
VAT Group AG
UBS Group AG
Roche Holding AG
USA
RUS
CHE
Vladimir Putin
Donald Trump
Show more
17:34 20.05.2025
ubs warns relocation could harm long term growth of swiss economy
17:08 13.05.2025
Swiss companies consider relocation amid rising tariffs and protectionism concerns
16:48 13.05.2025
Swiss executives benefit from undervalued share portfolios boosting their earnings
Swiss Franc
Novartis AG
Holcim Ltd.
UBS Group AG
Roche Holding AG
CHE
Vas Narasimhan
Mark L. Schneider
Thomas Schinecker
Sergio Ermotti
Severin Schwan
Jan Jenisch
Show more
06:04 11.05.2025
swiss ceos benefit from undervalued share packages boosting their bonuses
Swiss Franc
Novartis AG
Holcim Ltd.
UBS Group AG
Roche Holding AG
CHE
Vas Narasimhan
Mark L. Schneider
Thomas Schinecker
Sergio Ermotti
Severin Schwan
Jan Jenisch
Show more
20:47 09.05.2025
ubs rates roche holdings ag as buy amid investment considerations
13:16 25.04.2025
Roche Holdings AG maintains positive outlook in healthcare research and diagnostics
12:03 25.04.2025
ubs rates roche holdings ag as buy amid investment considerations
13:40 24.04.2025
Roche Holdings AG Receives Positive Outlook from UBS Amid Diverse Healthcare Innovations
12:27 24.04.2025
Swiss stock market edges up as Oerlikon and Basilea report strong results
United States Dollar
Euro
Swiss Franc
Straumann Holding AG
Roche Holding AG
Lonza Group AG
ABB Ltd
Sandoz Group AG
Julius Bär Gruppe AG
Alstom SA
Novartis AG
Swiss Re AG
Nestlé S.A.
Zurich, Agence générale Christian Meier SA
OC Oerlikon Corp AG, Pfaffikon
DEU
USA
CHE
Show more
08:06 18.02.2025
Trending
Subcategory
Countries:
Companies:
Currencies:
People: